Taken from the Urologix 2003 Annual Report
in the market for the treatment of BPH comes from invasive therapies, such as
TURP, drug therapy and other minimally invasive treatments. There are six
well-recognized prescription drugs available in the
Competition in the market for minimally invasive treatments for BPH continues to grow.
Competitive devices include radio frequency (Medtronic), interstitial laser (Johnson & Johnson), side-firing laser (Laserscope), non-cooled, low energy microwave (TherMatrx, Inc.), high energy microwave with limited cooling (ACMI) and water-induced thermotherapy (ACMI). Celsion Corporation formed a strategic alliance with Boston Scientific Corporation for Boston Scientific to distribute a new microwave system for BPH upon approval from the FDA to market the device. Additional competitors may enter the market. We believe Cooled ThermoTherapy provides significant advantages over other minimally invasive BPH therapies. Because Cooled ThermoTherapy does not require punctures or incisions, it can be performed in the physician’s office or other outpatient environments without the need for anesthesia or intravenous sedation. Further, by combining microwave energy with cooling, we can drive heat deep into the prostate, creating lasting results while minimizing damage to the urethra, enhancing patient comfort and reducing complications.